HeraMED (ASX:HMD) - CEO & Co Founder, David Groberman
CEO & Co Founder, David Groberman
Source: TechInvest Magazine
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Medical technology company HeraMED (HMD) has received commitments to raise $2.32 million via a share placement
  • This placement forms part of a larger $3.82 million capital raising with the remaining $1.5 million to be raised by a share purchase plan
  • In regards to the placement more than 25 million shares will be issued to sophisticated and professional investors at a price of $0.09 each
  • For the share purchase plan, eligible shareholders will be able to purchase up to $30,000 worth of shares
  • HeraMED will use the $3.82 million to strengthen its balance sheet and speed-up the rollout of its digital pregnancy monitoring platform, HeraCARE
  • Company shares are down 4.35 per cent and are currently trading for 11 cents each

Medical technology company HeraMED (HMD) has received commitments to raise $2.32 million through a share placement.

This placement forms part of a larger $3.82 million capital raising with the remaining $1.5 million to be raised by a share purchase plan.

A total of 25,804,659 fully paid ordinary shares will be issued to sophisticated and professional investors at a price of $0.09 each.

This price represents a 21 per cent discount to the last closing price of $0.115 on May 29, and an 18 per cent discount to the five-day volume-weighted average price of $0.11.

“I am delighted by the support from both existing and new investors in this placement,” CEO and Co Founder David Groberman said.

“Since the start of COVID-19, theses been a substantial increase in interest in our telehealth maternity care platform from healthcare professionals globally and these funds will ensure we capitalise on these opportunities,” he added.

As previously stated, the remaining $1.5 million will be raised through a share purchase plan.

Eligible shareholders will be able to purchase up to $30,000 worth of new fully paid shares.

If there are less participants than estimated then HeraMED will allow sophisticated, professional, and other investors to take part.

However, it may not need to come to this as the company has already received bids for more than half.

HeraMED will use the money from both the placement and share purchase plan to strengthen its balance sheet and speed-up the rollout of its digital pregnancy monitoring platform, HeraCARE.

Company shares are down 4.35 per cent and are trading for 11 cents each at 1:47 pm AEST.

HMD by the numbers
More From The Market Online

Firebrick Pharma’s US launch of Nasal Spray is nothing to be sneezed at

Australian pharmaceutical developer, Firebrick Pharma (ASX:FRE) has launched its latest product, Nasodine Nasal Spray, in the…

AVITA Medical drops revenue forecast for Q1

AVITA Medical (ASX:AVH) provided an update on its anticipated revenue for Q1 2024 - and has…

Little Green Pharma heading into Q2 cashed up after record sales

Little Green Pharma (ASX:LGP) wound up Q1CY24 with $5M in cash after posting record sales of…

Recce Pharmaceuticals up 6% on new antibiotic production milestone

Recce Pharmaceuticals (ASX:RCE) is trading up more than 6 per cent after producing a 5000-dose batch…